Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 2,241 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: RNA sequencing Clear all
Completed No phase listed Observational

End-tidal Oxygen Can Reliably Predict the Arterial Partial Pressure of Oxygen Among Emergency Department Patients

NCT03842306
View directory record Official record
Conditions
Intubation Complication
Interventions
Not listed
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
18 Years and older
Enrollment
75 participants
Timeline
2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Oct 18, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)

NCT00395304
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate + montelukast, fluticasone propionate, fluticasone propionate + salmeterol
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
6 Years to 18 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 18, 2026, 5:03 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease

NCT06270316
View directory record Official record
Conditions
Fabry Disease
Interventions
AMT-191
Drug
Lead sponsor
UniQure Biopharma B.V.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 18, 2026, 5:03 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Grappling With Trauma: Brazilian Jiu-Jitsu for First Responders

NCT07783516
View directory record Official record
Conditions
Post-traumatic Stress Disorder (PTSD), Trauma and Stress Related Disorders, Occupational Stress, Emotional Regulation Difficulties, Anger Problems, Relational Problems, Irritability
Interventions
Brazilian Jiu-Jitsu Program
Behavioral
Lead sponsor
Sam Houston State University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Conroe, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 18, 2026, 5:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Virtual Reality (VR) for Stress Management

NCT06970652
View directory record Official record
Conditions
Stress, Resilience, Quality of Life, Depressive Symptoms, Anxiety, Sleep, Physical Activity
Interventions
virtual reality
Device
Lead sponsor
City University of New York, School of Public Health
Other
Eligibility
18 Years to 29 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 18, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Effect of RO7049389 on the Pharmacokinetics of Pitavastatin in Healthy Volunteers

NCT03717064
View directory record Official record
Conditions
Healthy Volunteers
Interventions
RO7049389, Pitavastatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 18, 2026, 5:03 AM EDT
Withdrawn Not applicable Interventional

Emotion Recognition Modification for Bipolar Disorder

NCT02613104
View directory record Official record
Conditions
Bipolar Disorder
Interventions
emotion recognition modification - sad>happy, emotion recognition modification - sad>happy control, emotion recognition modification - angry>happy, emotion recognition modification - angry>happy control
Other
Lead sponsor
Northwell Health
Other
Eligibility
16 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 18, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female Participants

NCT05579574
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986322, Loestrin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 18, 2026, 5:03 AM EDT
Not listed Not applicable Interventional

Comparing Cognitive Remediation Approaches for Schizophrenia

NCT04123223
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Cognitive Remediation, Computer Games
Behavioral
Lead sponsor
Wesleyan University
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Hartford, Connecticut • Middletown, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 14, 2020 · Synced Oct 18, 2026, 5:03 AM EDT
Completed No phase listed Observational

Natural History Study of SLC25A46 Mutation-related Mitochondriopathy

NCT04594590
View directory record Official record
Conditions
Neurodegenerative Disease, Hereditary, Mitochondrial Diseases, Optic Atrophy
Interventions
Mutation analysis
Genetic
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
0 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 18, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate QTc Prolongation With Quizartinib in Healthy Subjects Under Rapid Acceleration of Heart Rate

NCT06772246
View directory record Official record
Conditions
Healthy Subjects
Interventions
Quizartinib, Placebo
Drug · Other
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 18, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis

NCT01262118
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550 (tasocitinib)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
9
States / cities
Anniston, Alabama • Little Rock, Arkansas • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 18, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).

NCT00405080
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
GW679769 (Casopitant) oral tablets, Rifampin oral capsules
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 18, 2026, 5:03 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age

NCT06634797
View directory record Official record
Conditions
Healthy Volunteers
Interventions
mRNA-1273.712, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
12 Years to 30 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
24
States / cities
Phoenix, Arizona • Huntington Park, California • La Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 18, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants

NCT07097259
View directory record Official record
Conditions
Hypogonadism
Interventions
Test: Follitropin alfa, Reference: Follitropin alfa, Zoladex
Combination Product · Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 18, 2026, 5:03 AM EDT
Not yet recruiting Not applicable Interventional

Pedi-STAR: Surface Target Antibody-drug Conjugate (ADC) Antigen Expression in Relapsed/Refractory Pediatric Solid and CNS Tumors

NCT07793994
View directory record Official record
Conditions
CNS Tumor, Solid Tumor, Relapsed Cancer, Refractory Cancer, Pediatric Cancer
Interventions
Bulk RNA Sequencing, Immunohistochemistry (IHC)
Diagnostic Test
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 30 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 18, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence

NCT02888054
View directory record Official record
Conditions
Healthy
Interventions
lesinurad/allopurinol 200/300 FDC tablet, lesinurad 200 mg, allopurinol 300 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2017 · Synced Oct 18, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential

NCT06657105
View directory record Official record
Conditions
Healthy Participants
Interventions
EE/LNG, Baxdrostat
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 18, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

NCT04129931
View directory record Official record
Conditions
Asthma
Interventions
MCT, Clazakizumab, Broncho-Vaxom, Imatinib Mesylate, Cavosonstat, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years and older
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
29
States / cities
Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 18, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Relative Bioavailability of AZD8630 Following a Device and Formulation Transition in Healthy Participants.

NCT06531811
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD8630 (test formulation) via test inhaler, AZD8630 (reference formulation) via Monodose inhaler, Test inhaler, Monodose inhaler
Drug · Device
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 18, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Effect of Cefiderocol on the Pharmacokinetics (PK) of Midazolam in Healthy Participants

NCT05395104
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Midazolam, Cefiderocol
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 18, 2026, 5:03 AM EDT
Withdrawn Phase 1 Interventional

KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer

NCT02205463
View directory record Official record
Conditions
Esophageal Cancer, Stomach Cancer
Interventions
KD019
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2014 · Synced Oct 18, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Tacrolimus in Healthy Volunteers

NCT01430065
View directory record Official record
Conditions
Pharmacokinetics of ASP015K, Drug Interactions, Healthy Subjects
Interventions
ASP015K, Tacrolimus
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Oct 18, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of BPN14770 on Rosuvastatin

NCT07011992
View directory record Official record
Conditions
Healthy Participants
Interventions
Rosuvastatin, BPN14770
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 18, 2026, 5:03 AM EDT